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ABSTRACT
Gastrointestinal stromal tumors (GIST) arise within the interstitial cell of Cajal 
(ICC) lineage due to activating KIT/PDGFRA mutations. Both ICC and GIST possess 
primary cilia (PC), which coordinate PDGFRA and Hedgehog signaling, regulators 
of gastrointestinal mesenchymal development. Therefore, we hypothesized that 
Hedgehog signaling may be altered in human GIST and controls KIT expression. 
Quantitative RT-PCR, microarrays, and next generation sequencing were used to 
describe Hedgehog/PC-related genes in purified human ICC and GIST. Genetic 
and pharmacologic approaches were employed to investigate the effects of GLI 
manipulation on KIT expression and GIST cell viability. We report that Hedgehog 
pathway and PC components are expressed in ICC and GIST and subject to 
dysregulation during GIST oncogenesis, irrespective of KIT/PDGFRA mutation status. 
Using genomic profiling, 10.2% of 186 GIST studied had potentially deleterious 
genomic alterations in 5 Hedgehog-related genes analyzed, including in the PTCH1 
tumor suppressor (1.6%). Expression of the predominantly repressive GLI isoform, 
GLI3, was inversely correlated with KIT mRNA levels in GIST cells and non-KIT/
non-PDGFRA mutant GIST. Overexpression of the 83-kDa repressive form of GLI3 or 
small interfering RNA-mediated knockdown of the activating isoforms GLI1/2 reduced 
KIT mRNA. Treatment with GLI1/2 inhibitors, including arsenic trioxide, significantly 
increased GLI3 binding to the KIT promoter, decreased KIT expression, and reduced 
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INTRODUCTION
Gastrointestinal stromal tumor (GIST) is the most 
common sarcoma with an estimated annual incidence of 
6.8 cases per million people in the United States [1]. GIST 
is thought to arise from stem cells that differentiate toward 
the lineage of interstitial cells of Cajal (ICC), electrical 
pacemaker and neuromodulator cells of the gut [2-5]. ICC 
represent ~5% of the cells in the tunica muscularis [6] 
and their development depends upon KIT (v-kit Hardy-
Zuckerman 4 feline sarcoma viral oncogene homolog; 
CD117) receptor tyrosine kinase (RTK) expression and 
signal transduction. Approximately 95% of GIST express 
KIT [7]. GIST oncogenesis involves somatic activating 
alterations in KIT (75-80%) or platelet-derived growth 
factor receptor α (PDGFRA; <10%) [2]. In rare cases, 
GIST lack a mutant KIT or PDGFRA allele. These tumors 
may arise from mutations in KIT/PDGFRA signaling 
intermediates (e.g., NF1, BRAF, KRAS, HRAS) or 
deficiency in the mitochondrial succinate dehydrogenase 
(SDH) complex caused by inactivating SDH subunit (A-
D) mutations or epigenetic repression [2, 3, 8, 9]. Despite 
their molecular heterogeneity, most GIST share common 
characteristics, including expression and activation of KIT 
and PDGFRA. Indeed, depending on the tumor genotype, 
about half to three quarters of patients with advanced 
GIST respond to treatment with anti-KIT/PDGFRA 
tyrosine kinase inhibitors (TKIs) including the first-
line drug, imatinib mesylate (Novartis Pharmaceuticals, 
Switzerland). However, TKIs alone do not eradicate GIST 
cells, and more than 95% of patients eventually succumb 
to imatinib-resistant disease [2], necessitating the search 
for alternative therapeutic targets.
The Hedgehog signaling pathway is critical for 
the development of the gastrointestinal tract, including 
the growth of the underlying mesenchyme [10, 11]. 
Here, Hedgehog activation promotes the survival and 
proliferation of tunica muscularis progenitors [11]. During 
embryonic development, ectopic Hedgehog pathway 
activation in the murine pancreatic bud stimulates the 
differentiation of the surrounding mesoderm into gut-
like mesenchyme containing smooth muscle cells and 
KIT+ ICC-like cells [12]. Throughout life, the Hedgehog 
pathway is regulated by ligand-dependent and/or ligand-
independent mechanisms. With the aid of dispatched 
(DISP), the hedgehog ligands, sonic hedgehog (SHH) 
and indian hedgehog (IHH), are secreted and then bind 
to the patched 1 and 2 receptors (PTCH1 and PTCH2). In 
the absence of hedgehog ligands, PTCH1/2 bind to, and 
repress the activity of, the smoothened co-receptor (SMO). 
In turn, the GLI family of transcription factors remains 
in a balance favoring transcriptional repression, with 
GLI3 being proteasomally processed into a transcriptional 
repressor (GLI3R). However, in the presence of SHH/
IHH ligand binding to PTCH1/2 and their co-receptors, 
SMO inhibition is released, leading to transcriptional 
activation by GLI1 and GLI2, as well as reduced 
transcriptional repression by GLI3 [13]. Suppressor of 
fused (SUFU) functions as a tumor suppressor that inhibits 
the GLI transcription factors and suppresses the Hedgehog 
pathway [14]. Ultimately, Hedgehog signaling controls the 
expression of its own intermediates, including PTCH1, 
as well as genes that control cell proliferation, survival, 
epithelial-to-mesenchymal transition, stemness, and other 
developmental pathways [15].
Elevated Hedgehog signaling results from loss-
of-function mutations in PTCH1 and SUFU, gain-of-
function mutations in SMO, or overexpression of pathway 
activators including SHH/IHH ligands, SMO or GLI1/2, 
which can lead to aberrant cell growth and tumorigenesis 
[16]. However, only a small amount evidence has been 
accumulated to indicate a role for the Hedgehog pathway 
in GIST.[17] SHH, PTCH1, SMO, and GLI1 expression 
were detected by immunohistochemistry in one study 
[18], and chromosome 7p amplification was found to 
be associated with increased GLI3 expression [19]. 
Interestingly, GLI3 has been reported to repress KIT 
mRNA levels in ICC-like cells of the murine ureter [20], 
raising the possibility that GLI3 may contribute to the 
formation of a KITlow/- GIST cell pool [4] responsible, in 
part, for disease persistence during imatinib therapy [3]. 
Additionally, conditional PTCH1 inactivation in lysozyme 
M-expressing murine cells has been reported to lead to 
the development of PDGFRA+ GIST-like lesions [21]. 
Finally, it is known that optimal Hedgehog signaling in 
vertebrate cells requires primary cilia (PC) [22]. PC have 
been reported in murine, rat, rabbit, and human ICC [23, 
24], as well as in primary, recurrent and metastatic human 
GIST [25, 26], possibly developing under the control of 
the ICC and GIST marker, anoctamin 1 (ANO1) [27].
Here, we tested the hypothesis that the Hedgehog 
pathway contributes to GIST oncogenesis. We report 
that Hedgehog-related genes are robustly expressed in 
isolated human and murine ICC, ICC stem cells, and 
GIST, irrespective of mutation status. We also detected 
potentially significant genomic alterations in key 
Hedgehog pathway members (PTCH1, PTCH2, SMO, 
SUFU, GLI1) in 10% of GIST studied. We also found that 
GIST oncogenesis is associated with a shift in Hedgehog-
related gene expression relative to normal human ICC. 
viability in imatinib-sensitive and imatinib-resistant GIST cells. These data offer new 
evidence that genes necessary for Hedgehog signaling and PC function in ICC are 
dysregulated in GIST. Hedgehog signaling activates KIT expression irrespective of 
mutation status, offering a novel approach to treat imatinib-resistant GIST.
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Finally, we demonstrate reduced KIT expression in 
response to genetic or pharmacological blockade of 
GLI1/2 or overexpression of the repressor form of GLI3 
and show reduced cell viability in imatinib-sensitive and 
imatinib-resistant cells in response to pharmacological 
inhibition of Hedgehog signaling. Together, these results 
show that the Hedgehog pathway is a potential novel 
therapeutic target in TKI-resistant GIST. 
RESULTS
Murine GIST models express Hedgehog signaling 
components
Given that the Hedgehog pathway has been shown 
to control the development of the mouse gut mesenchyme 
[11], we sought to determine whether two commonly 
studied murine models of the mesenchymal tumor GIST 
express key Hedgehog signaling components (Shh, 
Ihh, Ptch1, Smo, Gli1, Gli2, Gli3). We studied KitV558∆/+ 
[28] and Kit+/K641E transgenic mice [29]. Total RNA was 
extracted from murine cecal GIST (n = 3 mice/model) 
and quantitative RT-PCR analyses were performed 
(Supplementary Figure S1A). Kit served as positive 
control and Actb served as loading control. Both models 
highly expressed several canonical Hedgehog pathway 
components, including Ihh, Ptch1, Smo, Gli1 and Gli2. 
There was little or no Shh or Gli3 expression in either 
model. We confirmed our findings by gel electrophoresis 
of the PCR products (Supplementary Figure S1B). These 
findings demonstrate that two murine models of GIST 
express several key Hedgehog signaling components.
Figure 1: GIST cell lines express Hedgehog signaling components. A. Following RNA extraction from GIST-T1 and GIST882, 
real-time RT-PCR analysis was performed for Hedgehog signaling components using the ΔCt method and ACTB as reference. Both cell 
lines were studied in three independent experiments, and each experiment was performed in triplicate. B. Agarose gel electrophoresis of 
two-step RT-PCR products shows expression of Hedgehog signaling components. C. Western blot analyses performed in whole cell lysates 
from GIST-T1, GIST882, and HEK293T cells (positive control) showing full length (FL, 190 kDa) or repressor (R, 83 kDa) isoforms of 
GLI3. β-actin served as loading control.
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Human GIST cell lines express Hedgehog 
signaling components
To determine if Hedgehog pathway mRNA 
expression is present in human GIST, we first studied two 
human gastric GIST cell lines, GIST-T1 and GIST882. 
Similarly to the KitV558∆/+ mice, GIST-T1 has an exon 11 
mutation (KIT V560-Y579Δ5), and GIST882 cells bear 
the same KIT mutation as the Kit+/K641E transgenic mice 
(K642E; exon 13). Using quantitative RT-PCR analyses, 
we evaluated the expression of the seven aforementioned 
Hedgehog pathway components (Figure 1A). While both 
cell lines lack expression of SHH and IHH (data not 
shown), we confirmed that the lines express high levels 
of PTCH1, SMO, GLI2, and GLI3. GIST882 had 3.3-
fold higher PTCH1, 2.0-fold higher SMO, and 6.0-fold 
higher GLI2 mRNA levels, as well as 2.2-fold lower GLI3 
mRNA expression relative to GIST-T1 (Figure 1A). Thus, 
GIST-T1 more robustly expresses GLI3, while GIST882 
more robustly expresses GLI2. We confirmed our findings 
by gel electrophoresis of the PCR products (Figure 1B). To 
assess whether the GLI3 protein was full length (GLI3FL, 
190 kDa) or proteolytically processed into the shorter 
GLI3 repressor (GLI3R, 83 kDa), we performed Western 
blot analysis with HEK293T cells as a positive control 
for expression of both GLI3 isoforms. We found both 
GIST-T1 and GIST882 to only express GLI3R without 
detectable GLI3FL (Figure 1C). These human gastric cell 
lines appeared to have lower IHH and GLI1 mRNA, but 
higher GLI3 mRNA levels than the murine cecal tumors, 
suggesting that these models have different Hedgehog 
pathway expression patterns.
Human GIST express Hedgehog signaling 
components
We next sought to confirm the expression of 
Hedgehog pathway components in freshly excised human 
tumors. Using the same human RT-PCR primers, we 
evaluated the Hedgehog pathway expression in three small 
bowel GIST (duodenal, jejunal, and ileal) from patients 
with KIT exon 9, 11, and 9 mutations, respectively. The 
human tumor data paralleled our cell line findings in that 
there was high PTCH1, SMO, GLI2, and GLI3 mRNA, 
but low GLI1 mRNA (Figure 2A-2B). Moreover, SHH and 
IHH mRNA expression was not detectable by quantitative 
RT-PCR analyses (data not shown). Therefore, the gastric 
GIST cell lines faithfully represent Hedgehog expression 
patterns in the human small intestinal tumors and the 
differences from mouse GIST appear to reflect species 
differences rather than differences in anatomical location 
or phenotypic changes during culturing.
The Hedgehog pathway is inherent to the ICC 
lineage
To investigate whether expression of the Hedgehog 
pathway occurs only after GIST oncogenesis or is 
inherent to the ICC lineage (i.e. the histogenetic source 
of GIST), we purified ICC by FACS from the stomach 
of patients undergoing bariatric surgery (n = 6). Gene 
expression was determined by Affymetrix microarrays 
and compared to dissociated, unfractionated gastric tunica 
muscularis samples (n = 4). By subsequent MetaCore™ 
Figure 2: Tumor tissues from human GIST express Hedgehog signaling components. A. Following RNA extraction from 3 
human GIST tumors, real-time RT-PCR analysis was performed for Hedgehog signaling components. mRNA expression was quantified 
by the ΔCt method using ACTB as reference. B. Agarose gel electrophoresis of two-step RT-PCR products shows expression of Hedgehog 
signaling components.
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Figure 3: Hedgehog signaling-related genes are differentially expressed by human gastric GIST, purified human ICC 
and their source tissue by microarray analysis. The list of Hedgehog-signaling-related genes was assembled by searching the 
Affymetrix Human Genome U133 Plus 2.0 microarray annotation file (na33) for Gene Ontology (GO) terms containing “smoothened” 
(biological process) and “hedgehog” (molecular function) (see specific GO terms in http://www.ebi.ac.uk/GOA). A. Heat map and 
unsupervised hierarchical cluster analysis of 69 human gastric GIST of various genotypes from the NCBI GEO series GSE17743 [32], 
GSE8167 [33], and GSE20708 [19] (see Supplementary Table S2 for details), FACS-sorted human ICC (n = 6), and unfractionated 
gastric tunica muscularis tissues (Tissue; n = 4). Expression values were determined using the MAS5 statistical algorithm. Significance 
of expression was determined by Wilcoxon signed-rank test. Heatmaps were assembled using probe set expression values with the lowest 
P value. Red and green colors specify high and low expression, respectively. Mutation status of each human GIST is indicated (WT: wild-
type as defined in the referenced studies). Cluster analysis of Hedgehog-related genes differentiated GIST from ICC but not GIST with 
different genotypes. B. Differential expression of Hedgehog signaling-related genes detected by microarray analysis in human gastric 
KIT-mutant GIST from the NCBI GEO series GSE17743 [32] (n = 15) and FACS-purified human ICC (n = 6). Expression values were 
determined by RMA. Unique gene lists were created by identifying the probe sets with the lowest Benjamini-Hochberg false discovery 
rate (BH FDR) Q values. Horizontal lines indicate threshold for significant log2 fold changes; red fill indicates Q < 0.05 from BH FDR. 
Differential expression with log2 fold change < -1 or >1 and Q < 0.05 was considered significant. Thirty-five Hedgehog-related genes were 
significantly overexpressed in GIST including Hedgehog signaling pathway and transcriptional target genes, as well as genes encoding for 
proteins responsible for anterograde cargo transport in PC. Notably, the 29 genes significantly overexpressed in ICC included the Hedgehog 
ligands SHH and IHH.
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analysis, unique genes significantly increased in ICC 
vs. their source tissue (log2 fold change >1, Benjamini-
Hochberg Q<0.05) were significantly enriched in genes 
assigned to the “Development_Hedgehog Signaling” 
network, which ranked 29th among biological process 
networks (Supplementary Table S1). This pathway was 
also significantly represented in gene sets differentially 
expressed in FACS-purified mouse small intestinal ICC-
MY and ICC-DMP [30], as well as in the mouse gastric 
ICC-SC line 2xSCS2F10 [31] relative to their own source 
tissues. These results indicate that the Hedgehog pathway 
is intrinsic to the cells of the ICC lineage in both mice and 
humans.
The Hedgehog pathway is altered during GIST 
oncogenesis
We next performed heat map and unsupervised 
hierarchical cluster analysis to investigate whether 
Hedgehog pathway expression patterns change during 
GIST oncogenesis. MAS5 expression values of unique 
genes in human gastric ICC (n = 6), unfractionated gastric 
tunica muscularis tissue (n = 4) and human gastric GIST 
microarrays (n = 69; Supplementary Table S2 [19, 32, 33]) 
and assigned to the Gene Ontology (GO) terms containing 
“smoothened” (biological process) and “hedgehog” 
(molecular function) were analyzed (Figure 3A). Cluster 
analysis clearly differentiated ICC from GIST. In contrast, 
GIST with different driver mutations (KIT exon 9 
and 11, PDGFRA exon 12, 14 and 18, as well as GIST 
lacking both KIT and PDGFRA mutations) could not be 
distinguished by their Hedgehog pathway expression 
patterns. Similarly to the results obtained by RT-PCR in 
small intestinal GIST, PTCH1, GLI3 and GLI2 but not 
IHH and SHH were expressed in gastric GIST. SMO was 
also expressed, albeit at lower levels.
We also performed pairwise analyses of GIST, ICC, 
and unsorted gastric tunica muscularis focusing on the 
same Hedgehog- and SMO-related gene set (Figure 3B 
and Supplementary Figure S2A-B). Thirty-five Hedgehog-
related genes were more than 2-fold overexpressed in 
GIST as compared to ICC. These included pathway 
signaling components such as PTCH1, RAB23, CDON, 
Table 1: Genomic alterations in the Hedgehog pathways genes detected in 19 of 186 GIST patients by the FoundationOne® 
assays.
Abbreviations: NGS, next-generation sequencing; VUS, variant of unknown significance; WT, wild type tumor (lacking 
mutations in KIT, PDGFRA, BRAF, KRAS, HRAS, NF1, and SDH subunits).
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HHIP, DISP1, and BOC. It is noteworthy that two of these 
are Hedgehog target genes, namely, PTCH1 and HHIP, 
function as readouts of pathway activity, and act to fine-
tune Hedgehog signals based upon negative feedback 
loops. Given the reported presence of primary cilia (PC) 
in GIST [25, 26], as well as the importance of PC in 
Hedgehog signaling transduction, it is also noteworthy 
that four proteins responsible for anterograde trafficking 
of cargo in PC, namely, KIF3A (encoding kinesin family 
member 3A), IFT52 (intraflagellar transport 52), IFT88 
(intraflagellar transport 88), and IFT172 (intraflagellar 
transport 172), were significantly overexpressed in 
GIST as compared to ICC (Figure 3B). Overall, the top 
7 overexpressed (>16-fold) genes in GIST relative to 
ICC (in descending order) are HIPK2 (homeodomain-
interacting protein kinase 2), IFT52, FOXF1 (forkhead 
box F1), RB1 (retinoblastoma 1), PtTCH1, RAB23, and 
TGFBR2 (transforming growth factor beta receptor II). 
In contrast, 29 genes were more than 2-fold decreased in 
GIST as compared to ICC, including SHH, IHH, GAS1, 
FKBP8, SUFU, and GLI3. Overall, the 7 most under-
expressed (>8-fold) genes in GIST relative to ICC were 
ZIC1 (Zic family member 1), FGFR3 (fibroblast growth 
factor receptor 3), GPC2 (glypican 2), SHH, FGF9 
(fibroblast growth factor 9), SFRP1 (secreted frizzled-
related protein 1), and NKX6-1 (NK6 homeobox 1). Taken 
together, these findings corroborate our earlier quantitative 
RT-PCR analyses demonstrating that Hedgehog-related 
genes are expressed in GIST, and indicate that many 
critical signaling components, including those of PC, are 
increased during the transformation from ICC to GIST 
regardless of the specific mutation driving oncogenesis.
Human GIST possess genomic alterations in 
Hedgehog signaling components
In addition to transcriptional alterations, GIST may 
also contain potentially pathogenic mutations in Hedgehog 
pathway members. To investigate this possibility, we 
performed comprehensive genomic profiling using the 
FoundationOne® next-generation sequencing assay panel 
in a separate cohort of 191 GIST from 186 patients. In 
this cohort, 19 of 186 patients’ tumors (10.2%) possessed 
genomic alterations in 5 Hedgehog-related genes analyzed 
(i.e., PTCH1, PTCH2, SMO, SUFU, and GLI1) (Table 1). 
The average age at diagnosis of this GIST subset was 54.3 
± 19.4 (median 58 years old) with male predominance 
(male: 63.2%; female: 36.8%). Three GIST (1.6%) of the 
entire cohort had likely deleterious genomic alterations in 
PTCH1. Of these three tumors, two also had KIT exon 11 
mutations, and one had an NF1 mutation. The remaining 
GIST had “variants of unknown significance” (VUSes) 
in all 5 genes, which were predicted to be deleterious 
by at least 2 out of 4 prediction tools (SIFT, PolyPhen, 
MutationTaster, and/or MutationAssessor). These variants 
included 7 in PTCH1, 3 in PTCH2, 4 in SMO, 2 in SUFU, 
and 6 in GLI1. In addition, these 19 Hedgehog-altered 
tumors had known oncogenic mutations in KIT (n = 13, 
68.4%), PDGFRA (n = 1, 5.3%), NF1 (n = 1, 5.3%), 
and SDHA (n = 1, 5.3%). Three tumors (15.8%) had no 
known driver mutations in KIT, PDGFRA, NF1, KRAS, 
HRAS, or SDHx subunits. These so-called “wild-type” 
(WT) GIST had predicted deleterious variants in SUFU 
and GLI1. Taken together, somatic mutations in a subset 
of Hedgehog pathway genes were found in about 10% of 
GIST that we analyzed, raising the possibility that these 
genes may act as modifier genes in the development and 
progression of GIST.
KIT expression inversely correlates with GLI3 
expression
Having identified that the Hedgehog pathway is 
genomically and transcriptionally dysregulated in the 
progression from ICC to GIST, we investigated how this 
pathway may intersect with known oncogenic drivers 
of GIST. An earlier report by Cain and colleagues 
demonstrated that GLI3 represses the expression of 
KIT mRNA in murine ureteral ICC-like cells [20]. To 
determine if GLI3 could be negatively regulating KIT 
mRNA expression in GIST, we further analyzed the 
quantitative RT-PCR data generated in the GIST cell lines 
(n = 3 independent experiments). This analysis showed an 
inverse relationship between GLI3 and KIT mRNA levels 
as the GIST-T1 cell line expressed less KIT and more 
GLI3 (ratio: 0.38) than the GIST882 line, which expressed 
KIT and GLI3 at a ratio of 1.98 (Figure 4A).
To extend the validity of this finding to GIST 
tumors, we analyzed KIT expression in relation to GLI1, 
GLI2 and GLI3 expression in 46 gastric GIST microarrays 
from GSE17743 [32] and GSE20708 [19]. We found no 
significant correlation between the expression of KIT 
and any of the GLI genes in the entire combined dataset. 
However, in WT GIST (defined as GIST lacking KIT and 
PDGFRA mutations; n = 7), KIT and GLI3 expression 
were inversely correlated (R2 = 0.753, P = 0.011; 
Figure 4B). Taken together, expression of the Hedgehog 
transcription factor, GLI3, inversely correlates with KIT 
mRNA levels in GIST cells (Figure 4A) and in non-KIT/
non-PDGFRA mutant GIST tumors (Figure 4B).
Genetic modulation of GLI transcription factors 
controls expression of Hedgehog target genes
Using small interfering RNAs (siRNAs) and 
gene overexpression, we next investigated the effects 
of modulating GLI1, GLI2, and GLI3 on the expression 
of the known Hedgehog target gene, PTCH1, and KIT. 
Due to GIST-T1 cells’ resistance to electroporation, we 
focused on the GIST882 cell line. Forty-eight hours 
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Figure 4: Genetic modulation of GLI transcription factors controls KIT expression. A. Using quantitative RT-PCR, GLI3 
and KIT expression were analyzed in two GIST cell lines (n = 3 independent experiments). Note inverse relationship between GLI3 and KIT 
mRNA in GIST-T1 and GIST882 cells. B. KIT mRNA expression is inversely correlated with GLI3 mRNA expression in the wild-type (WT) 
subset (n = 7) of GIST microarrays in the NCBI GEO series GSE17743 [32] and GSE20708 [19]. Results from linear regression (solid line) 
and Pearson product moment correlation are shown. Dashed and dotted lines represent 95% confidence intervals for the regression and the 
population, respectively. C. Genetic inhibition of GLI1 and GLI2 reduces expression of PTCH1 and KIT in GIST cells. GIST882 cells were 
co-transfected with GLI1 and GLI2 siRNA or corresponding scrambled sequences (n = 3) and analyzed for GLI1, GLI2, PTCH1 and KIT 
expression by quantitative RT-PCR 48 h later. D. GLI3 moderates KIT expression in KIT+ GIST cells. GIST882 cells were electroporated 
with GLI3 siRNA, corresponding scrambled sequence, GLI3R plasmid or empty vector. At 48 h, GLI3 was successfully knocked down 
with resultant increased KIT mRNA expression as compared to scrambled siRNA (n = 3). In contrast, in GIST882 cells electroporated 
with GLI3R plasmid, KIT mRNA decreased at 48 h relative to empty vector (n = 3). E. GLI3R inhibits PTCH1 expression in GIST cells. 
GIST882 cells were transfected with GLI3R plasmid or empty vector and GLI3 and PTCH1 mRNA expression was analyzed at 48 h. F. 
GLI3R inhibits KIT expression in imatinib-resistant, KIT+ GIST cells. GIST48IM cells were transfected with GLI3R plasmid or empty 
vector and GLI3 and KIT mRNA expression was analyzed at 48 h. P-values are indicated in the panels.
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following introduction of siRNAs targeting GLI1 or GLI2 
or corresponding non-targeting (scrambled) sequences 
by nucleofection, GLI1 and GLI2 mRNA was reduced 
by 76% (n = 3, P = 0.0049) and 38% (n = 3, P = 0.24; 
not shown), respectively. KIT mRNA was only variably 
or marginally reduced by GLI1 knockdown (55%, n = 3, 
P = 0.08) or GLI2 knockdown (19%, n = 3, P = 0.15; 
not shown). Given the overlapping functions of GLI1 and 
GLI2, we assessed the effect of simultaneous knockdown 
of both genes 48 hours after introduction of siRNAs 
targeting GLI1 and GLI2 as compared to non-targeting 
sequences. In combination, GLI1 and GLI2 siRNAs 
reduced GLI1 expression by 84% (P = 0.0013) and GLI2 
expression by 81% (P < 0.0001). Concomitantly, PTCH1 
mRNA decreased by 80% (P < 0.0001) and KIT mRNA 
decreased by 71% (P = 0.0027) (Figure 4C). Thus, the two 
activating forms of GLI positively regulate the expression 
of the Hedgehog target gene, PTCH1, as well as the 
putative Hedgehog target gene, KIT, in GIST882.
We next assessed the role of the Hedgehog 
transcriptional repressor, GLI3, in KIT transcriptional 
regulation. In GIST882 cells, a 10% reduction of GLI3 
mRNA (n = 3, P = 0.16) was associated with a 62% (P 
= 0.04) increase in KIT mRNA expression (Figure 4D). 
Conversely, inducing GLI3 overexpression by transfection 
with a GLI3R plasmid (repressor form; n = 3; control: 
empty vector) resulted in a 63% decrease (P = 0.001) in 
KIT mRNA expression (Figure 4D). We also examined 
whether the established Hedgehog target gene PTCH1 
was similarly subject to transcriptional downregulation 
by GLI3 in GIST882 cells. Indeed, a 44% increase in 
GLI3R (P = 0.0064) by GLI3R overexpression resulted 
in a 46% decrease (P = 0.0002) in PTCH1 mRNA levels 
(Figure 4E). The effect of GLI3R overexpression was 
then assessed in the imatinib-resistant GIST48IM line 
possessing KIT exon 11 and 17 mutations. Compared 
to empty vector, a 5.3-fold GLI3R overexpression (P = 
0.0019) resulted in a 54% decrease (P = 0.015) in KIT 
mRNA expression (Figure 4F), but only an 8% decrease 
in PTCH1 mRNA expression (not shown). To determine 
if the GLI3 transcription factor directly or indirectly 
regulates KIT mRNA expression, we performed GLI3 
chromatin immunoprecipitation (ChIP) assays. Both 
GIST-T1 and GIST882 cells were treated with the GLI1/2 
inhibitor, arsenic trioxide (ATO; 4 μM) [34, 35] or vehicle 
control for 48 hours. Chromatin fragments were pulled 
down by anti-GLI3 antibodies and PCR-amplified to 
analyze GLI3 binding to the KIT promoter (Supplementary 
Figure S3). We detected GLI3 binding to regions covering 
and immediately flanking the KIT transcription start site 
which was increased by ATO, especially in the region 
immediately upstream of the transcription start site 
in GIST882 cells, where a 2.5-fold (P = 0.02) greater 
occupancy was found in the presence of GLI1/2 blockade. 
Taken together, similarly to blocking the activating GLI 
isoforms (i.e., GLI1/2), increasing the repressor form of 
GLI (i.e., GLI3R) inhibits KIT expression, while blocking 
GLI3 mRNA increases KIT expression. GLI3R-mediated 
transcriptional downregulation of KIT is via direct 
promoter binding and is preserved in imatinib-resistant 
GIST cells. These findings are consistent with our gene 
expression data and an earlier report in mouse ureteral 
ICC-like cells [20].
Pharmacologic GLI1/2 inhibition reduces KIT 
expression
We next utilized the GLI1/2 inhibitor GANT61 
(Gli-ANTagonist 61; 10 μM) [36] to simultaneously 
inhibit both activating GLI transcription factors. GANT61 
reduced KIT mRNA expression by 50% (P = 0.035) in 
GIST882 cells but not in GIST-T1 cells (n = 3/cell line/
group, Figure 5A). In contrast, the aforementioned GLI1/2 
inhibitor, arsenic trioxide (ATO; 4 μM) [34, 35], which 
is an FDA-approved drug for the treatment of acute 
promyelocytic leukemia, reduced KIT mRNA by 60.2% 
in GIST-T1 cells and 38.0% in the GIST882 line (n = 3/
cell line/group; Figure 5A). In the imatinib-resistant line 
GIST48IM, ATO (4 μM) decreased KIT mRNA expression 
by 66.6%, (P = 0.0001), whereas imatinib (10 μM) and 
sorafenib (10 μM) had no effect (Figure 5B). Thus, 
simultaneous pharmacologic inhibition of GLI1 and 
GLI2 decreased KIT mRNA expression in both imatinib-
sensitive and imatinib-resistant GIST [34, 35], similarly 
to genetic silencing of GLI1 and GLI2 in GIST882 cells 
(Figure 4C).
Pharmacologic GLI1/2 inhibition reduces GIST 
cell viability
Suppression of KIT mRNA or pharmacological 
inhibition of KIT signaling in GIST cells is sufficient to 
induce apoptosis and tumor regression [37]. However, 
imatinib-resistance due to secondary mutations in KIT 
has emerged as a major clinical problem [2]. In order 
to exploit the GIST lines’ dependence on constitutive 
KIT expression irrespective of KIT mutation status, 
we performed MTT viability assays and 11-point dose 
response curves with imatinib (positive control) or ATO 
using both imatinib-sensitive (GIST-T1 and GIST882) 
and imatinib-resistant (GIST48IM) cells (n = 3/cell line/
drug/concentration). While both GIST-T1 and GIST882 
were sensitive to imatinib (IC50 = 2.5 nM and 212 nM, 
respectively), GIST48IM was resistant to imatinib (IC50 
> 10 μM) (Figure 5C). On the other hand, all three lines 
were sensitive to ATO, irrespective of mutation status 
(Figure 5D). The IC50 values were 0.6 μM, 2.7 μM, and 
8.8 μM, respectively. These represent clinically achievable 
concentrations [38]. To assess this effect genetically, we 
simultaneously knocked down GLI1 and GLI2 expression. 
This alone had minimal effects on cell viability (data not 
Oncotarget78235www.impactjournals.com/oncotarget
shown), suggesting that the ATO-induced inhibition of KIT 
mRNA may not have sufficiently reduced KIT protein and 
KIT signaling within the time period of the experiments. 
However, pharmacologically targeting Hedgehog/GLI 
signaling, decreasing KIT expression, and likely hitting 
Hedgehog-independent ATO targets (e.g., reactive oxygen 
species, phosphatase inhibition or JNK/AP-1 activation 
of redox-sensitive enzymes [39]) in GIST represents a 
novel approach to disrupting GIST dependence upon KIT 
signaling for survival, irrespective of imatinib-sensitive or 
imatinib-resistant KIT mutation status.
DISCUSSION
We provide evidence that the Hedgehog pathway 
is inherent to the human ICC lineage and altered during 
GIST oncogenesis. Relative to freshly purified human 
ICC, tumor cells lose expression of both Hedgehog 
ligands while increasing expression of genes associated 
with primary ciliogenesis and Hedgehog pathway target 
genes, indicating ligand-independent signaling. These 
transcriptomic alterations occur irrespective of mutation 
status or anatomic location suggesting that Hedgehog is 
a conserved signaling pathway in GIST. We also report 
Hedgehog-related genomic alterations in up to 10% of 
human GIST, including deleterious mutations in the 
Hedgehog pathway inhibitor PTCH1 occurring at a rate 
of 1.6% in tumors. Using transcriptomic, genetic and 
pharmacologic approaches, we also demonstrate that 
the Hedgehog pathway predominantly activates KIT 
expression in human GIST and may be a cell viability 
factor in both imatinib-sensitive and imatinib-resistant 
GIST cell lines. Consistent with these data, we observed 
inhibition of KIT mRNA expression and reduced viability 
in response to ATO (an FDA-approved drug with multiple 
effects, including GLI1/2 inhibition) in GIST cell lines 
with different KIT mutations, including GIST cells with 
Figure 5: Pharmacologic modulation of Gli transcription factors decreases KIT expression and cell viability. A. GIST-T1 
and GIST882 cells were treated for 48h with 10 µM GANT61 or 4 µM arsenic trioxide (ATO). By qRT-PCR, GLI1/2 pan-inhibition reduced 
KIT mRNA expression versus 0.1% DMSO control in GIST-T1 (ATO only) and GIST882 cells (both GANT61 and ATO). ‡ P < 0.002. 
** P < 0.005; n = 3/cell line/treatment/group. B. Imatinib- and sorafenib-resistant GIST48IM cells were treated with imatinib (10 µM), 
sorafenib (10 µM) or ATO (4 µM) for 48 h. By qRT-PCR, ATO but not imatinib or sorafenib inhibited KIT mRNA expression versus 0.1% 
DMSO control. * P < 0.05, # P < 0.0002; n = 3/group. C.-D. Eleven-point dose-response curves in GIST-T1, GIST882 and GIST48IM cells 
treated with 10 µM-169 nM imatinib (C) or ATO (D) for 72, 120 and 120 h, respectively. Cell viability was assessed by MTT assay. ATO 
dose-dependently inhibited GIST-T1, GIST882 and GIST48IM cell viability.
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KIT mutation that renders GIST resistant to TKI therapies. 
Importantly, the ATO doses resulting in these effects 
appear to be therapeutically relevant [38]. Together, our 
findings show that the Hedgehog pathway is expressed in 
ICC and plays a fundamental role in the pathobiology of 
GIST. Inhibiting Hedgehog/GLI signaling and downstream 
KIT expression, as well as other ATO targets, represents 
a novel and clinically potentially realizable approach 
to disrupting GIST dependence on KIT signaling for 
survival. This is especially important in imatinib-resistant 
tumors, which represent the most important challenge in 
the treatment of advanced GIST [2].
Our current findings significantly expand upon 
earlier reports demonstrating a relationship between 
GIST and the Hedgehog pathway. In 31 gastric GIST, 
one study reported expression of SHH (in 58.1% of 
tumors), PTCH1 (in 77.4%), SMO (in 80.6%), and 
GLI1 (in 58.1%) by immunohistochemistry [18]. There 
was strong correlation between SHH protein and risk of 
GIST recurrence. Contrary to this study, in two GIST cell 
lines and 72 human gastric and small intestinal GIST, 
we found low or undetectable expression of Hedgehog 
ligands and GLI1. The difference in these findings may 
lie in technical factors, as the antibodies employed in ref. 
[18] are not recommended for use in FFPE sections by 
the manufacturer. More recently, Pelczar et al. suggested 
a relationship between GIST and the Hedgehog pathway 
by describing PDGFRA+ “GIST-like tumors” in mice with 
conditional Ptch1 inactivation in lysozyme M-expressing 
cells  [21]. However, the cells-of-origin could not be 
identified and, together with the GIST-like tumors, lacked 
KIT expression, complicating interpretation. In contrast, 
we find that KIT-expressing human GIST cell lines and 
tumors overexpress PTCH1, a readout of Hedgehog 
signaling, with PTCH1 mRNA expression increasing 
from normal ICC to GIST. We also detected inactivating 
PTCH1 mutations in nearly 2% of genomically sequenced 
tumors, and nearly 10% of all GIST studied had one or 
more potentially deleterious variants in PTCH1 and 
other Hedgehog pathway genes. While most appeared 
to represent passenger mutations, three tumors lacked 
known driver mutations in KIT, PDGFRA, BRAF, KRAS, 
HRAS, NF1, and SDH subunits but had potentially 
deleterious variants in GLI1 and SUFU. However, the 
true significance of these mutations is unclear as their 
oncogenic capacity was only assessed bioinformatically, 
but not experimentally.
The Hedgehog pathway is one of several 
developmental signaling pathways known to be important 
in tumorigenesis. Several of the Hedgehog-related 
genes overexpressed in GIST are involved in regulating 
cell proliferation (CD3E, HIPK1/2, and PTCH1), cell 
differentiation (CDON and FOXF1) and apoptosis (CD3E 
and HIPK1/2). Other genes include regulators of primary 
cilia formation (C2CD3, KIF3A, IFT172, IFT52, and 
IFT88), and negative regulators of the Hedgehog pathway 
(HHIP, RAB23, and TULP3). Developmental signaling 
pathways tend to intersect. Indeed, several of the altered 
transcripts in GIST are also related to the Wnt, Notch, 
BMP and FGF pathways. The Wnt and Notch pathways 
are important in GIST biology [40, 41], and collagen triple 
helix repeat containing 1 (CTHRC1), an activator of Wnt/
planar cell polarity-Rho signaling, was shown to induce 
GIST migration and invasion, as well as correlated with 
recurrence risk score, disease-free survival and overall 
survival in 412 GIST patients [40]. HES1, a Notch and 
Hedgehog pathway target gene known to suppress gene 
transcription, was found to induce growth arrest and 
decrease KIT expression, reducing GIST viability [41]. 
We now demonstrate that the Hedgehog pathway in ICC 
and GIST also includes GLI3R-mediated transcriptional 
repression of KIT, which appears to represent an internal 
“brake” mechanism limiting the effects of GLI1/2-
induced KIT expression. Similarly to blocking the 
activating GLI1/2 isoforms, increasing GLI3R inhibited 
KIT expression, while blocking GLI3 mRNA increased 
KIT expression. These findings, together with our results 
showing that GLI1/2 inhibition by ATO increased KIT 
promoter occupancy by GLI3 indicates that the Hedgehog 
pathway likely regulates KIT transcription by a “push-
pull” mechanism. These findings are consistent with 
our gene expression data and an earlier report in mouse 
ureteral ICC-like cells [20]. Molecular progression of 
GIST involves sequential accumulation of chromosomal 
losses and gains [42, 43], including frequent 7p13 
amplification associated with GLI3 overexpression in 
nearly 20% of tumors [19]. Dominance of GLI3-mediated 
transcriptional repression may contribute to reduced or 
lost KIT expression seen in a subset of TKI-treated GIST 
and in ICC/GIST precursors [3-5].
We also found GIST to highly express four genes 
(KIF3A, IFT52, IFT88, and IFT172), which are associated 
with PC function in several cancers. Conditional deletion 
of KIF3A or IFT88 in basal cell carcinoma leads to ciliary 
elimination and strong inhibition of tumorigenesis induced 
by mutant SMO [44]. In contrast, ablation of PC enhances 
brain tumor growth induced by activated GLI2 [45]. These 
paradoxical effects are consistent with a dual opposing 
function of PC in regulating Hedgehog signal transduction 
[44]. We here show that GIST cells lack expression of 
Hedgehog ligands, but overexpress GLI2 in the presence 
of PC, which activates the Hedgehog pathway [22]. In 
this context, the PC produces the repressor form of GLI 
(i.e., GLI3R) in order to counterbalance GLI2 activation. 
Under the control of the ICC and GIST marker, anoctamin 
1 (ANO1) [27], the function of the PC is mediated by the 
IFT machinery, which supports Hedgehog and PDGFRA 
signal transduction along the axoneme [22]. For IFT 
trafficking to occur, the microtubule plus-end directed 
motor kinesin-II (including KIF3A) and the IFT-B 
protein complex (including IFT52, IFT88, and IFT172) 
are necessary. We now show that these PC genes are 
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expressed in GIST, consistent with previous reports that 
primary, recurrent, and metastatic GIST have PC [25, 26]. 
Thus, ICC and GIST have PC, which are important for 
Hedgehog and PDGFRA signaling; and GIST overexpress 
critical PC machinery involved in normal and aberrant PC 
signaling.
In conclusion, our findings provide a new and 
expanded understanding for the role of the Hedgehog 
pathway in the development and progression of GIST. 
We now provide the first evidence that Hedgehog 
developmental signaling is present in the ICC lineage and 
is dysregulated in GIST, irrespective of KIT/PDGFRA 
mutations or tumor location, adding Hedgehog to the 
growing list of developmental signaling pathways 
important in GIST. Further studies will define the utility of 
Hedgehog-related pharmacological agents in the treatment 
of imatinib-resistant GIST.
MATERIALS AND METHODS
Human GIST Samples 
After obtaining informed consent, tumor samples 
were collected from 3 GIST patients undergoing resections 
at the University of California, San Diego (UCSD). All 
procedures were approved by the UCSD Institutional 
Review Board (IRB) (#090401). Pathological diagnosis 
was made by an experienced pathologist based on light 
microscopic analysis of formalin-fixed, paraffin-embedded 
(FFPE) tissue sections and sections labeled with antibodies 
against KIT and ANO1. KIT and PDGFRA activating 
mutations were analyzed by PCR and sequencing (ARUP 
Laboratories, Salt Lake City, UT). Excess tumor tissue 
was used for research purposes.
Tissue Source of Human ICC and Isolation by 
Fluorescence-Activated Cell Sorting (FACS)
De-identified human gastric tissues that were 
used for the preparation of primary ICC were obtained 
as surgical excess tissue from 14 patients undergoing 
bariatric operations (see Supplementary Materials and 
Methods) [46]. All procedures including waiver of the 
consent were approved by the Mayo Clinic IRB (protocol 
#07-003371). The tissues were dissected, dissociated and 
labeled using previously published protocols [47] modified 
for human samples.
RNA Preparation from ICC Isolates for 
Microarray Analysis
Total RNA was prepared from FACS-purified 
human ICC using the Total RNA Purification Kit (Norgen 
Biotek Corp, Thorold, ON, Canada) and purified using 
the MinElute Reaction Cleanup Kit (Qiagen, Hilden, 
Germany). RNA quality was assessed with the Agilent 
RNA 6000 Pico Kit (Agilent, Waldbronn, Germany). The 
Ovation Pico WTA system (NuGEN, San Carlos, CA) 
was used to prepare cDNA by single primer isothermal 
amplification (SPIA®) for hybridization to the Affymetrix 
GeneChip Human Genome U133 Plus 2.0 array 
(Affymetrix, Santa Clara, CA).
Sources of Human GIST and ICC-related 
Microarray Data
The human GIST microarray data from 69 patients 
discussed in the current study were retrieved from the 
National Center for Biotechnology Information Gene 
Expression Omnibus (NCBI GEO; http://www.ncbi.nlm.
nih.gov/geo/) and are accessible through GEO Series 
accession numbers GSE17743 [32] (n=29 gastric GIST), 
GSE8167 [33] (n=23 gastric GIST), and GSE20708 [19] 
(n=17 gastric GIST) (see Supplementary Table S2 for 
details). Microarray data from FACS-sorted human ICC 
(n=6), HP+ cells (n=3), and NOT ICC (n=1), as well as 
unfractionated gastric tunica muscularis tissues (n=4) 
generated in this study are accessible through GEO 
SuperSeries accession number GSE77839. Microarray 
data previously generated from mouse small intestinal 
myenteric ICC (ICC-MY) and deep muscular plexus ICC 
(ICC-DMP), as well as their source tissues are accessible 
through GSE7809; gene expression data from 2XSCS2F10 
ICC-SC and their source tissue are accessible through 
GSE60854.
Analysis of Human Gastric GIST and ICC 
Microarray Data
Gene expression was compared between human 
gastric ICC, human gastric GIST, mouse gastric 
2xSCS2F10 ICC-SC, mouse intestinal ICC-MY/ICC-DMP 
and their respective unfractionated source tissues, as well 
as between human gastric ICC and gastric KIT-mutant 
GIST from GSE17743 (n=15). Probe-level data were pre-
processed by robust multiple-array analysis (RMA) and 
analyzed for differential gene expression by the empirical 
Bayes approach with Benjamini-Hochberg adjustment 
using software packages in Bioconductor (https://www.
bioconductor.org/ [30]). Differential expression with 
log2 fold change <−1 or >1 and Q<0.05 was considered 
significant. Unique gene lists were created by identifying 
the probe sets with the lowest Benjamini-Hochberg false 
discovery rate Q-values. Process networks in gene sets 
significantly overexpressed in human and mouse ICC and 
mouse ICC-SC were identified by MetaCore™ analysis 
(GeneGo, Thomson Reuters Corp., New York). Gene 
expression data for human GIST (GSE17743, GSE8167, 
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and GSE20708), purified human ICC, NOT ICC, HP+ 
cells, as well as human gastric tunica muscularis tissues 
were also quantified using the MAS5 algorithm in the 
Bioconductor package affy. Significance of expression was 
determined by Wilcoxon signed-rank test, and heat maps 
were assembled using probe set expression values with the 
lowest P-value. Unsupervised hierarchical clustering was 
performed using gplots.
Cell Culture 
We obtained the GIST-T1 line containing a KIT 
exon 11 (V560-Y579Δ5: imatinib-sensitive) mutation 
[48] from Dr. T. Taguchi (Kochi Medical School, 
Japan), the GIST882 line containing a KIT exon 13 
(K642E: imatinib-sensitive) mutation [49] from Dr. S. 
Singer (Memorial Sloan-Kettering Cancer Center, New 
York), and the GIST48IM lines containing KIT exon 11 
(homozygous V560D: imatinib-sensitive) and KIT exon 17 
(heterozygous D820A: imatinib-resistant) mutations from 
Dr. J. Fletcher (Dana-Farber Cancer Center, Boston, MA) 
[50]. All cell lines were cultured as previously reported. 
HEK293T cells were grown in DMEM with 10% FBS, 1% 
penicillin/streptomycin (Mediatech), and 2 mM glutamine 
(Mediatech).
Statistical Analysis 
Statistical analyses were performed using GraphPad 
Prism 4 (GraphPad Software, La Jolla, CA) or SigmaPlot 
10 (with SigmaStat plug-in; Systat Software, Inc., San 
Jose, CA). Results are expressed as the mean ± SEM or 
SD as appropriate. Comparisons between two groups were 
performed using the Student’s t-test (Stata 9.0, StataCorp, 
College Station, TX). Statistical significance was accepted 
at the 5% level.
Other Materials and Methods
Standard methods (i.e., real-time reverse-
transcription PCR, transient transfection by 
electroporation, Western blotting, chromatin 
immunoprecipitation, and cell viability assays) and 
additional details are described in the Supplementary 
Materials and Methods.
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Implications
This study discovers that the Hedgehog pathway 
activates KIT expression in the ICC/GIST lineage and is 
increased in GIST regardless of mutation status, offering 
a novel approach to pharmacologically target imatinib-
resistant tumors. 
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